CRP and Mental deterioration: Within the Prospective Study of Pravastatin in the Elderly at Risk (PROSPER) trial - a trial of pravastatin versus placebo among 5804 men and women, who were 70 to 82 years of age [11] - we associated plasma CRP concentrations with cognitive decline and investigated to what extent cardiovascular risk factors explain this association.